Jonah Lupton
CEO & CIO of FirstWave Capital, Long-Biased Growth
Aehr Test Systems' FY2027 guidance for 160–200% revenue growth is conservative, built on backlog, pending deals and pilot programs, and it should beat the top end by at least 15–20%, implying about 245% growth. That gives the stock a shot at $150-plus within 12 months, especially if it is on track for $300 million-plus of FY2028 revenue; FY2029 revenue could reach $474 million. The post-earnings fade that erased most of the gains is an opportunity. x.com x.com
Aehr Test Systems' fiscal 2027 guidance looks conservative, leaving room for much higher revenue. It guided to at least $130-150 million, up 160-200%, against the sell side's $85 million. The earnings call dropped breadcrumbs of upside from several significant pilot programs with large semiconductor customers, and Aehr skipped guiding low to secure easy beats, suggesting $180-200 million is possible. At under 15x forward revenue, the valuation looks very fair for 200-300% growth. x.com x.com
Aehr Test Systems stands to benefit because testing is a bottleneck to scaling AI chips. Testing demand is about to surge. Investors did not question its price-to-sales ratio at 120, despite the current P/S objection. x.com x.com
Aehr Test Systems had a great quarterly call, and the stock now sits at a key pivot. x.com
Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com
Aehr Test Systems has validated its burn-in thesis as bookings convert to revenue and evaluation customers move into production, with AI processor power, silicon photonics and hybrid bonding raising the value of burn-in testing. Q4 bookings rose to $60.7M from $11.1M, effective backlog reached $100.6M, twice fiscal 2026 revenue, and fiscal 2027 guidance of $130M-$150M implies 160%-200% growth. The results lead optical production and could renew momentum in the optical theme. x.com x.com x.com … Show more
Aehr Test Systems is an upper-tier opportunity for anyone who believes the AI build-out is still in its early innings, after giving back nearly all of its 40% post-earnings gain. Guidance of about $140M at the midpoint implies roughly 170% growth over FY26 at about 20x sales, not cheap but a big opportunity alongside a $100M backlog. Many names map back to Aehr. x.com
Aehr Test Systems' valuation looks ahead of its fundamentals after a strong turnaround quarter. Q4 FY2026 revenue rose 33% to $18.8 million with a return to GAAP profit, bookings hit a record $60.7 million and effective backlog topped $100.6 million. FY2027 guidance of $130-150 million implies 160-200% growth, so the post-earnings run prices in high expectations that depend on shipping FOX-XP systems on schedule without margin erosion. TRT is preferred for now. x.com x.com
Aehr Test Systems is going to crush forward estimates, with its thesis well under way. Per @wallstengine, it received a record $41M production order from its lead hyperscale customer for package-level burn-in of custom AI processor ASICs, and second-half fiscal bookings now exceed $92M, above its prior $60-80M outlook. x.com
Aehr Test Systems has become a key picks-and-shovels supplier to the AI chip boom, with its Sonoma platform the go-to system for reliability testing of high-power AI processors. On April 16, 2026, it announced a $41M follow-on order, its largest ever, from an unnamed hyperscale AI chip leader for custom AI ASIC testing, with revenue from fiscal 2027. Backlog doubled to $38.7M, second-half FY26 bookings exceed $92M, and FY26 should hit the high end of $45-50M guidance. x.com
Aehr Test Systems' bull case looks overstated on a detailed financial model, summarized in a table for investors meeting CEO Gayn at the William Blair conference. x.com
Aehr Test Systems sells the only machines that burn-in test chips at industrial scale, catching failures on the wafer before costly packaging and GPU downtime. Burn-in looks set to become mandatory, with growth inflecting in 2027-2028 as co-packaged optics arrives and its market compounding with packaging cost. Much of the bull case is priced in: at about $4B, or 28x forward sales on ~$140M guidance, it needs roughly $400M of FY29 revenue at a generous 10x sales. x.com x.com x.com
